S. Korean firm seeks FDA nod to test stem cell drug for osteoarthritis

05/8/2013 | BioSpectrum Asia

South Korea's RNL Bio submitted an investigational new drug application to the FDA for RNL-JointStem, its adipose-based stem cell treatment for osteoarthritis. If the application is approved, the firm could begin midstage trials in the U.S. next quarter. RNL-JointStem has been tested in Phase I and II studies approved by Korean regulators.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC